Close the acquisition of Alexion Pharmaceuticals, Inc
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Feb 2021
- Due
- 30 Sep 2021
- Delivered
- 21 Jul 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the proposed acquisition by the Company of Alexion Pharmaceuticals, Inc. (Alexion), anticipated to close in Q3 2021.”
What we found
Evidence strength A What the grades mean
AstraZeneca completed the acquisition of Alexion Pharmaceuticals on July 21, 2021, which is within the third quarter of 2021.
-
A Astrazeneca plc 20-F filed 2022-02-22
“on 21 July 2021 the Company acquired Alexion Pharmaceuticals Inc. for consideration of $41,058 million.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Acquisition close
- Indicative materiality
- High rules
- Action
- Close
- Deliverable
- Alexion Pharmaceuticals, Inc. acquisition
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to regulatory approval; subject to shareholder approval
- Depends on
- Regulatory, Shareholder, Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Astrazeneca plc? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-AZN-023695 · Corrections policy